| Cat.No.: | BSM-0029 |
| Product Name: | CYC-116 |
| CAS No.: | 693228-63-6 |
| Abbr: | CYC-116(AURKA, AURKB, KDR) |
| Synonyms: | RP5-1167H4.6, AIK, ARK1, AURA, AURORA2, BTAK, PPP1R47, STK15, STK6, STK7 |
| Product Overview: | Inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2) |
| Description: | CYC116 is an orally active small molecule multi-kinase inhibitor with antineoplastic activity. CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death. |
| Molecular Weight: | 368.46 |
| Purity: | > 95%; >99% |
| Stability: | 2 years -20 centigrade Powder1 month -4 centigrade in DMSOMore than one month -80 centigrade in DMSO |
| Storage: | -20°C |
| Targets: | Aurora kinases A, Aurora kinases B, vascular endothelial growth factor receptor 2 (VEGFR2) |
| Molecular Formula: | C18H20N6OS |
| Chemical Name: | 4-(2-amino-4-methylthiazol-5-yl)-N-(4-morpholinophenyl)pyrimidin-2-amine |
| Solubility: | DMSO > 112mg/mL Water >1mg/mL Ethanol > 4mg/mL |
| Warning: | For Research Use Only! Not For Use in Humans. |
USA
Enter your email here to subscribe.
Follow us on
Easy access to products and services you need from our library via powerful searching tools
